Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Keywords

Coronavirus disease 2019 (COVID-19)MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakRetrospective cohort studyVirologyMEDLINECohortInternal medicineBiologyDiseaseOutbreak

Affiliated Institutions

Related Publications

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas , Frederick J. Angulo , John M. McLaughlin +12 more

Following the emergency use authorisation of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the Ministry of Healt...

2021 The Lancet 1722 citations

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan , Noam Barda , Eldad Kepten +7 more

This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19-related outcomes, a finding consistent with...

2021 New England Journal of Medicine 2739 citations

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Carmit Rubin , Victoria Indenbaum , Ilana Tal +13 more

To assess the effectiveness of the BNT162b2 vaccine among health care workers and to examine possible correlates of protection and infectivity

2021 New England Journal of Medicine 1451 citations

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Jamie Lopez Bernal , Nick Andrews , Charlotte Gower +12 more

Abstract Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (includ...

2021 BMJ 1367 citations

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Barak Mizrahi , Sharon Alroy‐Preis , Nachman Ash +8 more

In this study involving participants who were 60 years of age or older and had received two doses of the BNT162b2 vaccine at least 5 months earlier, we found that the rates of c...

2021 New England Journal of Medicine 1205 citations

Publication Info

Year: 2021
Type: article
Volume: 398
Issue: 10309
Pages: 1407-1416
Citations: 1255
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1255

OpenAlex

Cite This

APA Style

                            
                                
                                    Sara Y. Tartof, 
                                
                                    Jeff Slezak, 
                                
                                    Heidi Fischer
                                
                                et al.
                            
                            (2021). 
                            Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. 
                            The Lancet
                            , 398
                            (10309)
                            , 1407-1416.
                            https://doi.org/10.1016/s0140-6736(21)02183-8
                        

Identifiers

DOI: 10.1016/s0140-6736(21)02183-8